Suche Medizinische Publikationen
Suche Abbildungen und Grafiken
Medizinprodukte - Labortechnik
Antidotarium (Stand 2012)
Phytokodex (Stand 2012)
Endoskopie in Österreich (Stand 2010)
Kardiologie in Österreich (Stand 2006)
Osteologie in Österreich (Stand 2016)
Fachbücher
Patientenliteratur
März W, Winkelmann BR HMG-CoA Reductase Inhibition in the Treatment of Atherosclerosis: Effects Beyond Lipid Lowering Journal für Kardiologie - Austrian Journal of Cardiology 2002; 9 (7-8): 284-294 Volltext (PDF) Summary Übersicht
| ||||||
Abbildung 2: Pravastatin - C-reaktives Protein Pravastatin and C-reactive protein. A. Relative risks of recurrent coronary events in patients with previous MI in the CARE trial according to the presence (both C-reactive protein and serum amyloid A (> 90th percentile) or absence of systemic inflammation and according to treatment group [93]. B. C-reactive protein in a subset of 472 participants of the CARE study who remained free of coronary event during the trial. Left panel: Median and mean values at baseline and at 5 years of follow-up. Right panel: Mean changes over time stratified according to changes in LDL cholesterol in the placebo and in the pravastatin group. Modified according to [95]. |
Abbildung 2: Pravastatin - C-reaktives Protein
Pravastatin and C-reactive protein. A. Relative risks of recurrent coronary events in patients with previous MI in the CARE trial according to the presence (both C-reactive protein and serum amyloid A (> 90th percentile) or absence of systemic inflammation and according to treatment group [93]. B. C-reactive protein in a subset of 472 participants of the CARE study who remained free of coronary event during the trial. Left panel: Median and mean values at baseline and at 5 years of follow-up. Right panel: Mean changes over time stratified according to changes in LDL cholesterol in the placebo and in the pravastatin group. Modified according to [95]. |